Vaccine Info

BVRS-GamVac-Combi MERS Vaccine

Authored by
Staff
Last reviewed
July 10, 2021
Share

BVRS-GamVac-Combi MERS Vaccine Description

BVRS-GamVac-Combi MERS Vaccine is a heterologous adenoviral-based vaccine. "BVRS-GamVac-Combi" is a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration.

Adenoviruses have been used in gene therapy and have also been researched for use in vaccines for decades. An adenovirus can be used as a vector, or carrier, to deliver a gene to cells with instructions to make a protein required for the body to function properly. Think of the adenovirus vector as an envelope with a message inside.

Headquartered in Moscow, Russia, the Gamaleya Research Institute of Epidemiology and Microbiology, previously known as the N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology, is a Russian medical research institute. The center was founded in 1891 as a private laboratory. Since 1949 it bears the name of Nikolai Gamaleya, a pioneer in Russian microbiology studies.

BVRS-GamVac-Combi MERS Vaccine Indication

BVRS-GamVac-Combi MERS Vaccine is indicated to prevent Middle East Respiratory Syndrome (MERS). MERS-CoV is another form of coronavirus and causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. Human-to-human transmission is amplified among household contacts and in healthcare settings, stated the ECDC. And, scientific evidence suggests that people are infected through direct or indirect contact with infected dromedary camels.

MERS-CoV was first reported in the Kingdom of Saudi Arabia in 2012. The outbreak of MERS-CoV in South Korea during 2015 involved 186 cases, including 38 fatalities.

From January 2021 to May 31, 2021, nine MERS-CoV cases have been reported in Saudi Arabia (8) and the United Arab Emirates (1), including five deaths.

BVRS-GamVac-Combi MERS Vaccine Dosage

Phase 1 study - the safety of prime-boost vaccination with component 1 and component 2 with an interval of 21 days in half and full dose.

BVRS-GamVac-Combi MERS Vaccine News

January 14, 2021 - Phase 1 study update: The study aims to assess the safety and immunogenicity of heterologous adenoviral-based vaccine against MERS - BVRS-GamVac-Combi.

December 20, 2020 - The Journal of Biomedical Science published a study: Coronavirus vaccine development: from SARS and MERS to COVID-19.

BVRS-GamVac-Combi MERS Vaccine Clinical Trials

BVRS-GamVac-Combi MERS Vaccine is currently recruiting for a Phase 1/2 clinical trial. The estimated Study Completion Date is December 31, 2021